- Cell Line-derived Xenograft Models Development Services
- Syngeneic Models Development Services
- Humanized Mouse Models Development Services
- Genetically Engineered Mouse Models Development Services
- Patient-derived Xenograft Models Development Services
Mouse Models Development Services for Glioma
Contact usEmerging from the glial cell networks permeating the CNS, gliomas constitute 80% of malignant brain tumors, with glioblastoma demonstrating particularly dismal 5-year survival rates below 5%. The microenvironmental complexity of these lesions—marked by blood-brain barrier infiltration capacity and tumor-associated macrophage interactions—necessitates advanced preclinical systems bridging translational gaps. Alfa Cytology’s neuroscience division deploys orthotopic PDX models with intact perivascular niches and CRISPR-edited murine platforms incorporating IDH1 R132H mutations, empowering precise therapeutic discovery across glioma subtypes.
Our Capabilities
Alfa Cytology offers a comprehensive suite of mouse model development services specifically designed for glioma research. Our services include:
Customized Mouse Models
Your Trusted Partner In Preclinical Study
- Pharmacokinetics & Toxicology Evaluation
- Efficacy Model Development
- Longitudinal Treatment Response Monitoring
FAQs
What glioma modeling systems are available?
Our portfolio encompasses genetic mutation-specific GEMMs and orthotopic platforms maintaining native tumor microenvironment characteristics through precise intracranial engraftment techniques.
How do customized models enhance research outcomes?
Tailored systems enable subtype-specific investigation of molecular signatures and treatment resistance patterns, generating clinically translatable data for personalized therapeutic development.
What is your model development workflow?
Our five-phase protocol includes: 1) Collaborative needs assessment 2) Model parameter optimization 3) Surgical implantation/breeding 4) Multimodal monitoring 5) Comprehensive endpoint analysis.
What longitudinal monitoring capabilities exist?
We employ multiparametric MRI protocols coupled with bioluminescent tracking, enabling quantitative assessment of tumor dynamics and treatment responses throughout experimental timelines.